Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from China-based <a href="https://www.smartkarma.com/entities/8045" target="_blank" data-smartkarma-citation="entities:8045:1">Shanghai Fosun Pharmaceutical (Group) (2196 HK)</a>. In this insight, we will cover the company's background, its growth drivers, financial highlights, and score the deal in our ECM Framework. </p>

Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from China-based Shanghai Fosun Pharmaceutical (Group) (2196 HK). In this insight, we will cover the company's background, its growth drivers, financial highlights, and score the deal in our ECM Framework. 

Sisram Medical IPO: Israeli Technology, China Story

United States

Cynosure Inc. develops and manufactures lasers for medical and aesthetic treatment applications, including leg veins, hair removal, scar revision, port-wine birthmarks, facial spider veins, stretch marks, tattoos, and pigmented lesions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cynosure Inc A (CYNO US)

Sisram Medical IPO: Israeli Technology, China Story

Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)